Abstract: The present invention relates to a pharmaceutical composition for use in the prevention or treatment of nontuberculous mycobacterium infectious diseases, containing, as an active ingredient, a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof. The compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof, according to the present invention, can be used in the prevention or treatment of nontuberculous mycobacterium (NTM) infectious diseases.

Abstract: A pharmaceutical composition or a health functional food including a macrolide compound, a method of preparing the same, and a method using the same may be used to prevent or treat Mycobacterium sp. bacterial infection, such as tuberculosis, Hansen's disease, and non-tuberculous Mycobacterium sp. bacterial infections, or symptoms related thereto.

Abstract: Provided are a pharmaceutical composition for preventing or treating Mycobacterium sp. infection or a related symptom thereof, wherein the pharmaceutical composition includes a compound including a peptide represented by Formula 1, or an isomer, a derivative, a solvate, or a pharmaceutically acceptable salt thereof; and a method using the same. The pharmaceutical composition has anti-Mycobacterium tuberculosis activity against Mycobacteria, e.g., Mycobacterium tuberculosis, and palliates inflammatory response caused by Mycobacterium tuberculosis. Thus, the pharmaceutical composition may be used in preventing or treating Mycobacterium sp. infection or a related symptom thereof.

Abstract: Provided are a pharmaceutical composition for preventing or treating Mycobacterium sp. infection or a related symptom thereof, wherein the pharmaceutical composition includes a compound including a peptide represented by Formula 1, or an isomer, a derivative, a solvate, or a pharmaceutically acceptable salt thereof; and a method using the same. The pharmaceutical composition has anti-Mycobacterium tuberculosis activity against Mycobacteria, e.g., Mycobacterium tuberculosis, and palliates inflammatory response caused by Mycobacterium tuberculosis. Thus, the pharmaceutical composition may be used in preventing or treating Mycobacterium sp. infection or a related symptom thereof.

Abstract: The present invention relates to an repebody capable of binding specifically to interleukin-6 (IL-6) to inhibit the biological activity of IL-6, a polynucleotide encoding the repebody, a vector comprising the polynucleotide, a recombinant microorganism having introduced therein the polynucleotide or the vector, a method of producing the repebody using the recombinant microorganism, a composition for preventing or treating cancer, which comprises the repebody, and a method for preventing or treating cancer, which comprises administering the composition for preventing or treating cancer, which comprises the repebody. The repebody of the present invention significantly reduces the activity of signal transduction and activator of transciption3 (STAT3) and the concentration of interleukin-6, and thus can be widely used as an agent for preventing or treating IL-6-related diseases.

Abstract: The present invention relates to a method for improving a repebody protein comprising repeat modules and a nucleotide library encoding a repebody protein library for improving the repebody protein. More particularly, the present invention relates to a method for improving a repebody protein using a module evolution method of sequentially mutating repeat modules constituting the repebody protein, and a nucleotide library encoding a repebody protein library used to improve the protein. According to the module evolution method of the present invention, an improved repebody protein can be screened which has a high binding affinity and accordingly increased specificity and activity, and thus it is easy to express a repebody used as an inhibitor, a therapeutic agent, and an analysis means against a target substance.

Abstract: The present invention relates to an repebody capable of binding specifically to interleukin-6 (IL-6) to inhibit the biological activity of IL-6, a polynucleotide encoding the repebody, a vector comprising the polynucleotide, a recombinant microorganism having introduced therein the polynucleotide or the vector, a method of producing the repebody using the recombinant microorganism, a composition for preventing or treating cancer, which comprises the repebody, and a method for preventing or treating cancer, which comprises administering the composition for preventing or treating cancer, which comprises the repebody. The repebody of the present invention significantly reduces the activity of STAT3 and the concentration of interleukin-6, and thus can be widely used as an agent for preventing or treating IL-6-related diseases.